Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-463 Phase 1 Safety and PK Study in Healthy Adults
NCT06401213Phase 1Completed
- Sponsor
- Mediar Therapeutics
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MTX-463 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Mediar Therapeutics. Primary endpoints: Incidence of Treatment-Related Adverse Events at Day 82, Maximum Observed Serum Concentration at Day 82 and 4 more. Started Apr 2024; status: completed.
02
Drugs
MTX-463
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06401213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06401213.